Search Results

BioRestorative Therapies, Inc.(“BioRestorative” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx to the Company for intellectual property developed to address chronic lumbar disc disease have been made exclusive.

The Validation Institute, a third-party professional community that validates health care providers delivering superior results, has certified that patients who underwent Regenexx regenerative orthobiologic procedures to treat joint problems lower costs by avoiding surgery with excellent outcomes.

Interventional Orthopedic Solutions Rochester is establishing its commitment to excellence in the field of Regenerative Orthopedics by entering into a partnership with Regenexx®, a worldwide network of specially trained physicians providing advanced, research-driven, regenerative orthopedic treatments.

Regenexx®, a research-driven interventional orthobiologics network of physicians performing regenerative orthopedic procedures, has published its randomized controlled trial mid-term results showing primary ACL healing without the need for invasive surgery.

Partnership will allow Graham Company’s clients with self-funded health plans to access Regenexx’s non-surgical orthopedic alternatives as an employee benefits enhancement

Hylant excited to announce a unique partnership with Regenexx to offer access to non-surgical orthopedic alternatives to Hylant self-funded employer groups

Continental Benefits is excited to announce a unique partnership with Regenexx to offer access to non-surgical orthopedic alternatives to self-funded employer groups

Regenexx, the world’s largest, cohesive physician group dedicated to practicing advanced orthobiologics and the first to use stem cells in the treatment of many orthopedic injuries, is celebrating its 15th year since inception.

New research from Regenexx®, which provides advanced interventional orthobiologics, shows greater potential for treating osteoarthritis of the knee with cell-based therapies.

Regenexx Philadelphia and Regenexx Pittsburgh now provide self-funded employers with state-wide access to non-surgical treatments for orthopedic conditions benefiting employees while lowering healthcare spend by up to 80 percent